Sarepta Therapeutics (SRPT) PT Raised to $215 at RBC Capital; 'Vynodys Approval A Big Win'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $215.00 (from $200.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
